Lazard’s Global Healthcare Leaders Study finds, among other things:

• “Non-traditional pricing models may transform healthcare more than science over the next decade: almost half (47%) of healthcare C-level executives cite the adoption of value-based or risk-sharing pricing models as transformative over the next 5-10 years, compared to 38% who cite scientific breakthroughs.
• “The survey results suggest strongly that the move to value-based care in the U.S. will take place even under a new administration in Washington. Among U.S. healthcare executives surveyed after last year’s presidential election, 55% said they expect the majority of U.S. healthcare payments will be value-based before 2020.
• “Almost one-third of respondents in medical devices/tech/diagnostics and in healthcare services believe that non-traditional competitors will have a transformative impact on the industry in the next three to five years.
• “Healthcare executives most frequently cited M&A, industry partnerships and collaborations, including with non-traditional competitors, as enabling the transformation of the industry over the next 5-10 years.
• “More than half of respondents expected an increase in acquisitions of public companies over the next 18 months, and more than two-thirds expected an increase in private company acquisitions.”